Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1292–1296. doi: 10.1038/bjc.1995.250

Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.

C Wiltschke 1, M Krainer 1, A C Budinsky 1, A Berger 1, C Müller 1, R Zeillinger 1, P Speiser 1, E Kubista 1, M Eibl 1, C C Zielinski 1
PMCID: PMC2033813  PMID: 7779726

Abstract

Immunosuppression has been often associated with the course of malignant diseases. In the present study, the proliferation of peripheral blood mononuclear cells (PBMCs) in response to mitogenic stimulation with phytohaemagglutinin (PHA) was assessed prospectively in 90 patients with stage I-III breast cancer. Whereas PHA-induced proliferation of PBMCs derived from patients with breast cancer preoperatively was significantly decreased when compared with data obtained in healthy control individuals (P < 0.001), the degree of the defect in PHA-induced proliferation of PBMCs depended upon the tumour burden as manifested by tumour size and axillary lymph node involvement (P < 0.003 in each case). PHA-induced proliferation of PBMCs dropped significantly in patients who received adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and fluorouracil (CMF) after an observation period of 6 months (P < 0.01), but not in patients under adjuvant treatment with tamoxifen only. After an additional 6 months (i.e. 12 months after surgery), PHA-induced proliferation of PBMCs was similar in patients after adjuvant chemotherapy with CMF and in those receiving continued adjuvant tamoxifen treatment (P > 0.1), but in all patients still significantly decreased as compared with healthy controls (P < 0.001). When data obtained preoperatively and after 12 months were compared, it was found that out of 23 patients whose PBMCs had experienced a drop in their PHA-induced proliferation, 14 (61%) had developed metastatic disease within the subsequent 24 months (i.e. 36 months after surgery). In contrast, out of 59 patients whose PBMCs showed an increase in their PHA-induced proliferation within the first 12 months after surgery, only one (2%) presented with disease progression. We thus conclude that PHA-induced proliferation of PBMCs derived from patients with breast cancer depends upon the tumour load and is a good clinical predictor for the further course of the disease.

Full text

PDF
1292

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björkholm M., Wedelin C., Holm G., Ogenstad S., Johansson B., Mellstedt H. Immune status of untreated patients with Hodgkin's disease and prognosis. Cancer Treat Rep. 1982 Apr;66(4):701–709. [PubMed] [Google Scholar]
  2. Bonadonna G., Rossi A., Valagussa P., Banfi A., Veronesi U. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer. 1977 Jun;39(6 Suppl):2904–2915. doi: 10.1002/1097-0142(197706)39:6<2904::aid-cncr2820390677>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  3. Broder S., Waldmann T. A. The suppressor-cell network in cancer (second of two parts). N Engl J Med. 1978 Dec 14;299(24):1335–1341. doi: 10.1056/NEJM197812142992404. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., McGuire W. L. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):20–25. [PubMed] [Google Scholar]
  5. Contesso G., Jotti G. S., Bonadonna G. Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol. 1989 Mar;25(3):403–409. doi: 10.1016/0277-5379(89)90251-4. [DOI] [PubMed] [Google Scholar]
  6. Cunningham-Rundles S., Filippa D. A., Braun D. W., Jr, Antonelli P., Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst. 1981 Sep;67(3):585–590. [PubMed] [Google Scholar]
  7. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
  8. Giuliano A. E., Rangel D., Golub S. H., Holmes E. C., Morton D. L. Serum-mediated immunosuppression in lung cancer. Cancer. 1979 Mar;43(3):917–924. doi: 10.1002/1097-0142(197903)43:3<917::aid-cncr2820430320>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  9. Mikl J., Aiginger P., Czerwenka K., Kubista E., Salzer H., Sevelda P., Spona J., Staffen A., Zielinski C. C. Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on. Lancet. 1990 Mar 3;335(8688):541–541. doi: 10.1016/0140-6736(90)90775-z. [DOI] [PubMed] [Google Scholar]
  10. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992 Dec 11;258(5089):1795–1798. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  11. Nimberg R. B., Glasgow A. H., Menzoian J. O., Constantian M. B., Cooperband S. R., Mannick J. A., Schmid K. Isolation of an immunosuppressive peptide fraction from the serum of cancer patients. Cancer Res. 1975 Jun;35(6):1489–1494. [PubMed] [Google Scholar]
  12. Nordman E., Lehto I., Toivanen A. Immune functions and the prognosis of patients with solid tumours. Cancer Immunol Immunother. 1985;20(1):38–42. doi: 10.1007/BF00199771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. North R. J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984 May 1;159(5):1295–1311. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Penn I. The occurrence of cancer in immune deficiencies. Curr Probl Cancer. 1982 Apr;6(10):1–64. doi: 10.1016/s0147-0272(82)80002-0. [DOI] [PubMed] [Google Scholar]
  15. Stein J. A., Adler A., Efraim S. B., Maor M. Immunocompetence, immunosuppression, and human breast cancer. I. An analysis of their relationship by known parameters of cell-mediated immunity in well-defined clinical stages of disease. Cancer. 1976 Sep;38(3):1171–1187. doi: 10.1002/1097-0142(197609)38:3<1171::aid-cncr2820380319>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  16. Tichatschek E., Zielinski C. C., Müller C., Sevelda P., Kubista E., Czerwenka K., Spona J., Wolf H., Eibl M. M. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother. 1988;27(3):278–282. doi: 10.1007/BF00205452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. White D., Jones D. B., Cooke T., Kirkham N. Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer. 1982 Oct;46(4):611–616. doi: 10.1038/bjc.1982.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Whittaker M. G., Rees K., Clark C. G. Reduced lymphocyte transformation in breast cancer. Lancet. 1971 May 1;1(7705):892–893. doi: 10.1016/s0140-6736(71)92448-2. [DOI] [PubMed] [Google Scholar]
  19. Yu A., Watts H., Jaffe N., Parkman R. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl J Med. 1977 Jul 21;297(3):121–127. doi: 10.1056/NEJM197707212970301. [DOI] [PubMed] [Google Scholar]
  20. Zeillinger R., Kury F., Czerwenka K., Kubista E., Sliutz G., Knogler W., Huber J., Zielinski C., Reiner G., Jakesz R. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989 Jan;4(1):109–114. [PubMed] [Google Scholar]
  21. Zielinski C. C., Müller C., Tichatschek E., Aiginger P. Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy. Br J Cancer. 1989 Nov;60(5):712–714. doi: 10.1038/bjc.1989.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zielinski C. C., Stuller I., Dorner F., Pötzi P., Müller C., Eibl M. M. Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer. 1986 Oct 15;58(8):1648–1652. doi: 10.1002/1097-0142(19861015)58:8<1648::aid-cncr2820580812>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  23. Zielinski C. C., Tichatschek E., Müller C., Kalinowski W., Sevelda P., Czerwenka K., Kubista E., Spona J. Association of increased lytic effector cell function with high estrogen receptor levels in tumor-bearing patients with breast cancer. Cancer. 1989 May 15;63(10):1985–1989. doi: 10.1002/1097-0142(19890515)63:10<1985::aid-cncr2820631019>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES